Bad news for Novo Nordisk (NVO-1.51%) Friday was good news for Eli Lilly (LLY-0.08%) and Viking Therapeutics (VKTX 0.07%), its two main rivals in the field of weight loss drugs. This morning ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

of Novo Nordisk "Site Odense" in Kroghs park in Odense, Denmark, on December 16, 2024. (Photo by Mads Claus Rasmussen / Ritzau Scanpix / AFP) / Denmark OUT (Photo by MADS CLAUS RASMUSSEN/Ritzau ...

Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock.

LONDON/COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Digging deeper into the data, the estimated average ABR for patients on Novo’s drug was 1.7 versus 11.8 for patients with no prophylaxis, while the respective median ABR was zero for treated ...

Bagsværd, Denmark, 20 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...